Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00034925.xml
Hamostaseologie
DOI: 10.1055/a-2231-5277
DOI: 10.1055/a-2231-5277
Images in Thrombosis and Haemostasis
Multisite Thrombosis in a Patient with Paroxysmal Nocturnal Hemoglobinuria
Funding None.

Abstract
Case: Paroxysmal nocturnal hemoglobinuria (PNH) is an extremely rare bone marrow disorder caused by acquired mutations in the phosphatidylinositol glycan class A gene, which lead to a partial or total loss of the cellular complement regulators CD55 and CD59.[1] In addition to complement-mediated hemolysis and cytopenia, venous and arterial thromboses at multiple and/or unusual sites are a common complication and occur in up to 44% of patients in historic PNH cohorts.[1] [2]
Publication History
Received: 23 October 2023
Accepted: 18 December 2023
Article published online:
09 February 2024
© 2024. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
References
- 1 Panse J. Paroxysmal nocturnal hemoglobinuria: where we stand. Am J Hematol 2023; 98 (Suppl. 04) S20-S32
- 2 Hill A, Kelly RJ, Hillmen P. Thrombosis in paroxysmal nocturnal hemoglobinuria. Blood 2013; 121 (25) 4985-4996 , quiz 5105
- 3 Brodsky RA. How I treat paroxysmal nocturnal hemoglobinuria. Blood 2021; 137 (10) 1304-1309
- 4 Gerber GF, DeZern AE, Chaturvedi S, Brodsky RA. A 15-year, single institution experience of anticoagulation management in paroxysmal nocturnal hemoglobinuria patients on terminal complement inhibition with history of thromboembolism. Am J Hematol 2022; 97 (02) E59-E62